M&T Bank Corp Purchases Shares of 6,799 AtriCure, Inc. (NASDAQ:ATRC)

M&T Bank Corp bought a new position in AtriCure, Inc. (NASDAQ:ATRC) in the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor bought 6,799 shares of the medical device company’s stock, valued at approximately $208,000.

Several other institutional investors have also recently made changes to their positions in ATRC. Royce & Associates LP grew its stake in shares of AtriCure by 8.0% in the 3rd quarter. Royce & Associates LP now owns 64,785 shares of the medical device company’s stock worth $1,817,000 after acquiring an additional 4,800 shares in the last quarter. B. Metzler seel. Sohn & Co. Holding AG bought a new stake in shares of AtriCure in the 3rd quarter worth $880,000. Commerce Bank grew its stake in shares of AtriCure by 23.5% in the 3rd quarter. Commerce Bank now owns 11,470 shares of the medical device company’s stock worth $322,000 after acquiring an additional 2,181 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. grew its stake in shares of AtriCure by 39.4% in the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 185,819 shares of the medical device company’s stock worth $5,210,000 after acquiring an additional 52,533 shares in the last quarter. Finally, BNP PARIBAS ASSET MANAGEMENT Holding S.A. grew its stake in shares of AtriCure by 31.5% in the 3rd quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 500,649 shares of the medical device company’s stock worth $14,038,000 after acquiring an additional 119,929 shares in the last quarter. Institutional investors own 99.11% of the company’s stock.

Insider Buying and Selling at AtriCure

In other news, Director Karen Prange sold 6,100 shares of the stock in a transaction dated Wednesday, March 5th. The shares were sold at an average price of $38.12, for a total value of $232,532.00. Following the sale, the director now directly owns 17,828 shares of the company’s stock, valued at approximately $679,603.36. This represents a 25.49 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Insiders own 3.20% of the company’s stock.

Analyst Ratings Changes

Several analysts have recently issued reports on ATRC shares. Stifel Nicolaus upped their target price on shares of AtriCure from $36.00 to $48.00 and gave the stock a “buy” rating in a research note on Thursday, February 13th. JMP Securities restated a “market outperform” rating and set a $60.00 price target on shares of AtriCure in a research report on Monday, February 10th. Needham & Company LLC restated a “buy” rating and set a $51.00 price target on shares of AtriCure in a research report on Thursday, February 13th. Oppenheimer increased their price target on shares of AtriCure from $36.00 to $45.00 and gave the company an “outperform” rating in a research report on Thursday, February 13th. Finally, JPMorgan Chase & Co. increased their price target on shares of AtriCure from $40.00 to $51.00 and gave the company an “overweight” rating in a research report on Tuesday, February 11th. One research analyst has rated the stock with a hold rating and nine have given a buy rating to the company. Based on data from MarketBeat.com, AtriCure currently has a consensus rating of “Moderate Buy” and an average price target of $51.56.

AtriCure Price Performance

NASDAQ ATRC opened at $33.31 on Friday. The company has a market cap of $1.63 billion, a PE ratio of -35.06 and a beta of 1.53. AtriCure, Inc. has a 52 week low of $18.94 and a 52 week high of $43.11. The company has a quick ratio of 2.62, a current ratio of 3.65 and a debt-to-equity ratio of 0.13. The firm’s 50-day simple moving average is $38.10 and its two-hundred day simple moving average is $33.43.

About AtriCure

AtriCure, Inc develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, Europe, the Asia-Pacific, and internationally. The company offers Isolator Synergy Clamps, single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation, and ablate cardiac tissue with the same device; and the Coolrail device, which enables users to make longer linear lines of ablation.